摘要
目的 探讨肝细胞性肝癌 (HCC)中多药耐药基因mdr1的表达及其与肝癌临床病理特征、肿瘤多药耐药和患者预后的关系。方法 用免疫组化染色方法检测 5 6例HCC细胞中mdr1基因的表达 ,并结合临床病理指标进行统计分析。结果 5 6例HCC病例中mdr1基因的表达 :癌旁组织中 19例阳性 (3 3 .9% ) ,癌组织中 3 0例阳性 (5 3 .6% ) ,两者比较差异有显著性 (χ2 =4.3 9,P<0 .0 5 )。 48例初治患者中 2 2例阳性 (4 5 .8% ) ,8例复发者均为阳性 (10 0 % )。按肿瘤大小、数目、包膜有无、癌栓有无、分化程度、HBsAg等分组 ,其间mdr1表达差异无统计学意义。mdr1表达阳性组与阴性组 1、2、3年生存率比较 ,其差异无统计学意义。结论 mdr1在HCC中表达阳性率为 5 3 .6% ,其表达与肿瘤大小、数目、包膜有无、癌栓有无、分化程度、HBsAg和肝硬变情况无关 ;HCC具有原发性耐药。
Objective To explore the relationship between mdr1 gene expression of hepatocellular carcinoma (HCC) and pathological characteristics,chemotherapy and prognosis. Methods The mdr1 gene expression of HCC in 56 patients with the methods of immunohistochemistry was studied. The results were analysed with the pathological data by statistic methods. Results The positive expression of mdr1 gene in cancer tissues and pericancerous tissues of HCC were 30/56(53.6%) and 19/56 (33.9%) respectively. The difference was statistically significant (χ 2=4.39, P <0.05). The positive expression of mdr1 gene in cancer tissues of untreated patients and in recurrent patients were 22/48(45.8%) and 8/8(100%) respectively.The expression of mdr1 gene was not associated with tumor size, number, tumor thrombus, differentiation, HBsAg and liver cirrhosis. The patients with positive mdr1 expression had a shorter survival time than that of negative ones. But the difference was not statistically significant. Conclusion The positive expression of mdr1 in HCC is 53.6%. It is not associated with tumor size, number, tumor thrombus, tumor differentiation, HBsAg and liver cirrhosis. There are innate multidrug resistance in HCC.
出处
《中国普外基础与临床杂志》
CAS
2003年第4期370-372,375,共4页
Chinese Journal of Bases and Clinics In General Surgery
基金
国家自然科学基金资助项目 (项目编号 :39770 72 3)~~
